2019 Core Research Project (FIRE)

2019 ISAR Global Research Project 

The comparative effectiveness across severe asthma biologic classes (Anti-IL5 versus Anti-IgE) in patients eligible for both therapies (FIRE)

  • To describe severe asthma patients eligible for both Anti-IL5 and Anti-IgE.
  • To describe and compare clinical outcomes of patients receiving Anti-IL5 or Anti-IgE versus those maintained on OCS in terms of asthma control, exacerbations, and lung function.

Prof. David Price (Singapore)